SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin surges on getting USFDA nod for Pioglitazone Hydrochloride Tablets

09 Apr 2014 Evaluate

Lupin is currently trading at Rs. 978.00, up by 17.10 points or 1.78% from its previous closing of Rs. 960.90 on the BSE.

The scrip opened at Rs. 970.00 and has touched a high and low of Rs. 978.00 and Rs. 962.75 respectively. So far 11345 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1003.00 on 03-Mar-2014 and a 52 week low of Rs. 606.20 on 09-Apr-2013.

Last one week high and low of the scrip stood at Rs. 992.85 and Rs. 933.05 respectively. The current market cap of the company is Rs. 43499.18 crore.

The promoters holding in the company stood at 46.75% while Institutions and Non-Institutions held 43.17% and 10.08% respectively.

Pharma Major Lupin has received US Food and Drug Administration (US FDA) nod for Pioglitazone Hydrochloride Tablets. Pioglitazone tablets are to treat high blood sugar associated with diabetes.

Earlier in March, the company received final approval for its Doxycycline Capsules USP, 50 mg, 75 mg, and 100 mg from the United States Food and Drugs Administration (US FDA) to market a generic version of Aqua Pharmaceuticals' Monodox Capsules 50 mg, 75 mg, and 100 mg.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

 

Lupin Share Price

2478.30 36.20 (1.48%)
20-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1956.30
Dr. Reddys Labs. 1223.30
Cipla 1441.45
Lupin 2478.30
Zydus Lifesciences 1146.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: